October 11, 2025
The AAPS PharmSci 360 meeting remains one of the most influential gatherings for scientists, innovators, and decision-makers advancing pharmaceutical discovery and development. For Envol Biomedical, this event is more than a calendar staple — it’s a chance to connect directly with the scientific community we serve every day.
Envol and members of our team have been attending AAPS for many years because of the unique nature of both the organization and the event itself. PharmSci 360 brings together a deep cross-section of formulation scientists, discovery researchers, and bioanalytical chemists — the very sectors Envol supports through our integrated, preclinical, and analytical services. Being part of this discussion each year ensures our capabilities evolve in step with the needs of our partners and clients.
This year, Meghan Elizabeth, Director of Core Laboratories, and Matthew Beck, Director of Business Development, will be attending the meeting for Envol Biomedical.
Evolving Capabilities for the Discovery Community
We’re particularly excited this year to share updates about our expanding technologies and capabilities. Over the past year, Envol has continued to invest in new instrumentation, advanced imaging modalities, and staff training to stay ahead of the growing complexity of modern drug discovery.
Many AAPS attendees in the discovery space emphasize vendor flexibility and technical range — and we’ve made these priorities central to our growth strategy. Our teams now offer advanced imaging via MRI, PET, CT, ultrasound, and DEXA, alongside high-precision surgical models that support both exploratory and GLP-stage studies. These enhancements reinforce our ability to design customized study packages and accommodate special considerations across a wide range of therapeutic and delivery platforms.
Integrated Science, Delivered with Speed
Our conversations at AAPS often center on how to merge speed and scientific integrity — and that’s where Envol truly differentiates.
- MRI-Guided Neurosurgery & Targeted Delivery
Precision techniques that define the future of CNS research, supported by post-study imaging and real-time data interpretation. - Comprehensive Imaging Capabilities
Integrated imaging workflows that combine multiple modalities for deeper, multi-angle insight. - Core Lab & Biological Matrices Access
Streamlined sample analysis and matrix availability through our affiliated network, including NHP materials, minimizing project downtime. - GLP Toxicology with Real-World Timelines
A project management model designed to hit milestones without compromising quality.
Why AAPS Matters
For Envol, AAPS PharmSci 360 isn’t just about exhibiting — it’s about staying connected to the discovery pipeline. The conversations that happen here shape the next generation of drug development tools, methods, and expectations. This year, we look forward to reconnecting with friends, colleagues, and collaborators to discuss how our evolving capabilities can help them accelerate their preclinical programs with confidence.
Let’s Talk Discovery, Imaging, and Impact
Whether you’re designing early-stage pharmacology studies or preparing an IND-enabling program, a short conversation at AAPS could help you reimagine what’s possible. Stop by our booth or schedule a one-on-one meeting to discuss how Envol can support your next breakthrough.